In this study, we identified NSCLC patients harboring UBL biological process gene (ABL1, APC, LRP6, FUBP1, KEAP1, and TOP2) mutations, and this information could be used to stratify patients who might respond to the immune checkpoint inhibitor atezolizumab. This evidence concerns the gene TOP2A and non-small cell lung carcinoma.